Asymmetric dimethylarginine (ADMA): A promising biomarker for cardiovascular disease?

Current Topics in Medicinal Chemistry

Volumn 13, Issue 2, 2013, Pages 180-200

  Bouras, Georgios ^a   Deftereos, Spyridon ^a   Tousoulis, Dimitrios ^b   Giannopoulos, Georgios ^a,c   Chatzis, Georgios ^b   Tsounis, Dimitrios ^a   Cleman, Michael W ^c   Stefanadis, Christodoulos ^b  

^a G GENNIMATAS GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ADMA; Asymmetric dimethylarginine; Biomarker; Cardiovascular disease; Coronary artery disease; Diabetes mellitus; Heart failure; Hypertension

Indexed keywords

6 N, N' DIMETHYLARGININE; ARGININE; BIOLOGICAL MARKER; DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HOMOCYSTEINE; N (G), N (G) DIMETHYLARGININE; NITRIC OXIDE; PROTEIN ARGININE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

AGING; ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CONGENITAL HEART DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART ARRHYTHMIA; HEART FAILURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; INFLAMMATION; MASS SPECTROMETRY; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; RISK FACTOR; SHEAR STRESS; SMOKING;

AGING; AMIDOHYDROLASES; ARGININE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES COMPLICATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPERTENSION; MASS SPECTROMETRY; NITRIC OXIDE; OXIDATIVE STRESS; REFERENCE VALUES; RISK FACTORS; SMOKING;

EID: 84877827732     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611313020007     Document Type: Article

References (218)

1. Roger, V. L.; Go, A. S.; Lloyd-Jones, D. M.; Benjamin, E. J.; Berry, J. D.; Borden, W. B.; Bravata, D. M.; Dai, S.; Ford, E. S.; Fox, C. S.; Fullerton, H. J.; Gillespie, C.; Hailpern, S. M.; Heit, J. A.; Howard, V. J.; Kissela, B. M.; Kittner, S. J.; Lackland, D. T.; Lichtman, J. H.; Lisabeth, L. D.; Makuc, D. M.; Marcus, G. M.; Marelli, A.; Matchar, D. B.; Moy, C. S.; Mozaffarian, D.; Mussolino, M. E.; Nichol, G.; Paynter, N. P.; Soliman, E. Z.; Sorlie, P. D.; Sotoodehnia, N.; Turan, T. N.; Virani, S. S.; Wong, N. D.; Woo, D.; Turner, M. B. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation, 2012, 125, e2-e220.
2. Boger, R. H.; Maas, R.; Schulze, F.; Schwedhelm, E. Asymmetric dimethylarginine (ADMA) as a prospective marker of cardiovascular disease and mortality--an update on patient populations with a wide range of cardiovascular risk. Pharmacol Res, 2009, 60, 481-487.
3. Szuba, A.; Podgorski, M. Asymmetric dimethylarginine (ADMA) a novel cardiovascular risk factor--evidence from epidemiological and prospective clinical trials. Pharmacol Rep, 2006, 58 Suppl, 16-20.
4. Kakimoto, Y.; Akazawa, S. Isolation and identification of N-G,N-G-and N-G,N'-G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl-and galactosyl-delta-hydroxylysine from human urine. J Biol Chem, 1970, 245, 5751-5758.
5. Vallance, P.; Leone, A.; Calver, A.; Collier, J.; Moncada, S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet, 1992, 339, 572-575.
6. Boger, R. H. Asymmetric dimethylarginine: understanding the physiology, genetics, and clinical relevance of this novel biomarker. Proceedings of the 4th International Symposium on ADMA. Pharmacol Res, 2009, 60, 447.
7. Alderton, W. K.; Cooper, C. E.; Knowles, R. G. Nitric oxide synthases: structure, function and inhibition. Biochem J, 2001, 357, 593-615.
8. Tiefenbacher, C. P.; Kreuzer, J. Nitric oxide-mediated endothelial dysfunction--is there need to treat? Curr Vasc Pharmacol, 2003, 1, 123-133.
9. Pope, A. J.; Karuppiah, K.; Cardounel, A. J. Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production. Pharmacol Res, 2009, 60, 461-465.
10. Kielstein, J. T.; Bode-Boger, S. M.; Klein, G.; Graf, S.; Haller, H.; Fliser, D. Endogenous nitric oxide synthase inhibitors and renal perfusion in patients with heart failure. Eur J Clin Invest, 2003, 33, 370-375.
11. Tutarel, O.; Denecke, A.; Bode-Boger, S. M.; Martens-Lobenhoffer, J.; Lovric, S.; Bauersachs, J.; Schieffer, B.; Westhoff-Bleck, M.; Kielstein, J. T. Asymmetrical dimethylarginine--more sensitive than NT-proBNP to diagnose heart failure in adults with congenital heart disease. PLoS One, 2012, 7, e33795.
12. Zoccali, C.; Mallamaci, F.; Maas, R.; Benedetto, F. A.; Tripepi, G.; Malatino, L. S.; Cataliotti, A.; Bellanuova, I.; Boger, R. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int, 2002, 62, 339-345.
13. Furuki, K.; Adachi, H.; Enomoto, M.; Otsuka, M.; Fukami, A.; Kumagae, S.; Matsuoka, H.; Nanjo, Y.; Kakuma, T.; Imaizumi, T. Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography. Hypertens Res, 2008, 31, 1185-1189.
14. Bae, S. W.; Stuhlinger, M. C.; Yoo, H. S.; Yu, K. H.; Park, H. K.; Choi, B. Y.; Lee, Y. S.; Pachinger, O.; Choi, Y. H.; Lee, S. H.; Park, J. E. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol, 2005, 95, 729-733.
15. Yang, L.; Xiufen, Q.; Shuqin, S.; Yang, Y.; Ying, S.; Yanwei, Y.; Wei, F.; Dechun, Y. Asymmetric dimethylarginine concentration and recurrence of atrial tachyarrythmias after catheter ablation in patients with persistent atrial fibrillation. J Interv Card Electrophysiol, 2011, 32, 147-154.
16. Kielstein, J. T.; Bode-Boger, S. M.; Hesse, G.; Martens-Lobenhoffer, J.; Takacs, A.; Fliser, D.; Hoeper, M. M. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol, 2005, 25, 1414-1418.
17. Wilson, A. M.; Shin, D. S.; Weatherby, C.; Harada, R. K.; Ng, M. K.; Nair, N.; Kielstein, J.; Cooke, J. P. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vasc Med, 2010, 15, 267-274.
18. Notsu, Y.; Nabika, T.; Bokura, H.; Suyama, Y.; Kobayashi, S.; Yamaguchi, S.; Masuda, J. Evaluation of asymmetric dimethylarginine and homocysteine in microangiopathy-related cerebral damage. Am J Hypertens, 2009, 22, 257-262.
19. Kielstein, J. T.; Peter, C.; Adams, M. C. Cigarettes and ADMA: the smoke hasn't cleared yet. Hypertension, 2006, 48, E20; author reply E21.
20. Tousoulis, D.; Bouras, G.; Antoniades, C.; Marinou, K.; Papageorgiou, N.; Miliou, A.; Hatzis, G.; Stefanadi, E.; Tsioufis, C.; Stefanadis, C. Methionine-induced homocysteinemia impairs endothelial function in hypertensives: the role of asymmetrical dimethylarginine and antioxidant vitamins. Am J Hypertens, 2011, 24, 936-942.
21. Abbasi, F.; Asagmi, T.; Cooke, J. P.; Lamendola, C.; McLaughlin, T.; Reaven, G. M.; Stuehlinger, M.; Tsao, P. S. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol, 2001, 88, 1201-1203.
22. Boger, R. H.; Bode-Boger, S. M.; Szuba, A.; Tsao, P. S.; Chan, J. R.; Tangphao, O.; Blaschke, T. F.; Cooke, J. P. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation, 1998, 98, 1842-1847.
23. Palmer, R. M.; Ashton, D. S.; Moncada, S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature, 1988, 333, 664-666.
24. Boisvert, F. M.; Cote, J.; Boulanger, M. C.; Richard, S. A proteomic analysis of arginine-methylated protein complexes. Mol Cell Proteomics, 2003, 2, 1319-1330.
25. Bedford, M. T. Arginine methylation at a glance. J Cell Sci, 2007, 120, 4243-4246.
26. Bedford, M. T.; Clarke, S. G. Protein arginine methylation in mammals: who, what, and why. Mol Cell, 2009, 33, 1-13.
27. Vallance, P.; Leiper, J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol, 2004, 24, 1023-1030.
28. Nicholson, T. B.; Chen, T.; Richard, S. The physiological and pathophysiological role of PRMT1-mediated protein arginine methylation. Pharmacol Res, 2009, 60, 466-474.
29. Tang, J.; Frankel, A.; Cook, R. J.; Kim, S.; Paik, W. K.; Williams, K. R.; Clarke, S.; Herschman, H. R. PRMT1 is the predominant type I protein arginine methyltransferase in mammalian cells. J Biol Chem, 2000, 275, 7723-7730.
30. Herrmann, F.; Lee, J.; Bedford, M. T.; Fackelmayer, F. O. Dynamics of human protein arginine methyltransferase 1(PRMT1) in vivo. J Biol Chem, 2005, 280, 38005-38010.
31. Osanai, T.; Saitoh, M.; Sasaki, S.; Tomita, H.; Matsunaga, T.; Okumura, K. Effect of shear stress on asymmetric dimethylarginine release from vascular endothelial cells. Hypertension, 2003, 42, 985-990.
32. Boger, R. H.; Sydow, K.; Borlak, J.; Thum, T.; Lenzen, H.; Schubert, B.; Tsikas, D.; Bode-Boger, S. M. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res, 2000, 87, 99-105.
33. Antoniades, C.; Tousoulis, D.; Marinou, K.; Vasiliadou, C.; Tentolouris, C.; Bouras, G.; Pitsavos, C.; Stefanadis, C. Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines. Am J Clin Nutr, 2006, 84, 781-788.
34. Stuhlinger, M. C.; Oka, R. K.; Graf, E. E.; Schmolzer, I.; Upson, B. M.; Kapoor, O.; Szuba, A.; Malinow, M. R.; Wascher, T. C.; Pachinger, O.; Cooke, J. P. Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation, 2003, 108, 933-938.
35. Stuhlinger, M. C.; Stanger, O. Asymmetric dimethyl-L-arginine (ADMA): a possible link between homocyst(e)ine and endothelial dysfunction. Curr Drug Metab, 2005, 6, 3-14.
36. Vasileios, R.; Stergios, K.; Dimitrios, G. The Role of Asymmetrical Dimethylarginine (ADMA) in the Progression of Renal Disease. Nephrology (Carlton), 2012.
37. Teerlink, T. ADMA metabolism and clearance. Vasc Med, 2005, 10 (Suppl 1), S73-81.
38. McDonald, K. K.; Zharikov, S.; Block, E. R.; Kilberg, M. S. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric-oxide synthase may explain the arginine paradox. J Biol Chem, 1997, 272, 31213-31216.
39. Bogle, R. G.; MacAllister, R. J.; Whitley, G. S.; Vallance, P. Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol, 1995, 269, C750-756.
40. McDermott, J. R. Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit. Biochem J, 1976, 154, 179-184.
41. Ogawa, T.; Kimoto, M.; Watanabe, H.; Sasaoka, K. Metabolism of NG,NG-and NG,N'G-dimethylarginine in rats. Arch Biochem Biophys, 1987, 252, 526-537.
42. Ogawa, T.; Kimoto, M.; Sasaoka, K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem, 1989, 264, 10205-10209.
43. Murray-Rust, J.; Leiper, J.; McAlister, M.; Phelan, J.; Tilley, S.; Santa Maria, J.; Vallance, P.; McDonald, N. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol, 2001, 8, 679-683.
44. Nijveldt, R. J.; Teerlink, T.; van Guldener, C.; Prins, H. A.; van Lambalgen, A. A.; Stehouwer, C. D.; Rauwerda, J. A.; van Leeuwen, P. A. Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrol Dial Transplant, 2003, 18, 2542-2550.
45. Achan, V.; Broadhead, M.; Malaki, M.; Whitley, G.; Leiper, J.; MacAllister, R.; Vallance, P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol, 2003, 23, 1455-1459.
46. Leiper, J. M.; Santa Maria, J.; Chubb, A.; MacAllister, R. J.; Charles, I. G.; Whitley, G. S.; Vallance, P. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J, 1999, 343 (Pt 1), 209-214.
47. Tran, C. T.; Fox, M. F.; Vallance, P.; Leiper, J. M. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics, 2000, 68, 101-105.
48. Palm, F.; Onozato, M. L.; Luo, Z.; Wilcox, C. S. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol, 2007, 293, H3227-3245.
49. Gray, G. A.; Patrizio, M.; Sherry, L.; Miller, A. A.; Malaki, M.; Wallace, A. F.; Leiper, J. M.; Vallance, P. Immunolocalisation and activity of DDAH I and II in the heart and modification post-myocardial infarction. Acta Histochem, 2010, 112, 413-423.
50. Arrigoni, F. I.; Vallance, P.; Haworth, S. G.; Leiper, J. M. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation, 2003, 107, 1195-1201.
51. Hu, X.; Atzler, D.; Xu, X.; Zhang, P.; Guo, H.; Lu, Z.; Fassett, J.; Schwedhelm, E.; Boger, R. H.; Bache, R. J.; Chen, Y. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol, 2011, 31, 1540-1546.
52. Leiper, J.; Nandi, M.; Torondel, B.; Murray-Rust, J.; Malaki, M.; O'Hara, B.; Rossiter, S.; Anthony, S.; Madhani, M.; Selwood, D.; Smith, C.; Wojciak-Stothard, B.; Rudiger, A.; Stidwill, R.; McDonald, N. Q.; Vallance, P. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med, 2007, 13, 198-203.
53. Wang, D.; Gill, P. S.; Chabrashvili, T.; Onozato, M. L.; Raggio, J.; Mendonca, M.; Dennehy, K.; Li, M.; Modlinger, P.; Leiper, J.; Vallance, P.; Adler, O.; Leone, A.; Tojo, A.; Welch, W. J.; Wilcox, C. S. Isoform-specific regulation by N(G),N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res, 2007, 101, 627-635.
54. Tain, Y. L.; Baylis, C. Determination of dimethylarginine dimethylaminohydrolase activity in the kidney. Kidney Int, 2007, 72, 886-889.
55. Faraci, F. M. Hyperhomocysteinemia: a million ways to lose control. Arterioscler Thromb Vasc Biol, 2003, 23, 371-373.
56. Weis, M.; Kledal, T. N.; Lin, K. Y.; Panchal, S. N.; Gao, S. Z.; Valantine, H. A.; Mocarski, E. S.; Cooke, J. P. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation, 2004, 109, 500-505.
57. Kurz, K.; Teerlink, T.; Sarcletti, M.; Weiss, G.; Zangerle, R.; Fuchs, D. Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers. Pharmacol Res, 2009, 60, 508-514.
58. Ghebremariam, Y. T.; Erlanson, D. A.; Yamada, K.; Cooke, J. P. Development of a dimethylarginine dimethylaminohydrolase (DDAH) assay for high-throughput chemical screening. J Biomol Screen, 2012, 17, 651-661.
59. Linsky, T.; Wang, Y.; Fast, W. Screening for dimethylarginine dimethylaminohydrolase inhibitors reveals ebselen as a bioavailable inactivator. ACS Med Chem Lett, 2011, 2, 592-596.
60. Horowitz, J. D.; Heresztyn, T. An overview of plasma concentrations of asymmetric dimethylarginine (ADMA) in health and disease and in clinical studies: methodological considerations. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 851, 42-50.
61. Sydow, K.; Fortmann, S. P.; Fair, J. M.; Varady, A.; Hlatky, M. A.; Go, A. S.; Iribarren, C.; Tsao, P. S. Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin Chem, 2010, 56, 111-120.
62. Schulze, F.; Maas, R.; Freese, R.; Schwedhelm, E.; Silberhorn, E.; Boger, R. H. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest, 2005, 35, 622-626.
63. Boger, R. H.; Sullivan, L. M.; Schwedhelm, E.; Wang, T. J.; Maas, R.; Benjamin, E. J.; Schulze, F.; Xanthakis, V.; Benndorf, R. A.; Vasan, R. S. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation, 2009, 119, 1592-1600.
64. Teerlink, T. HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 851, 21-29.
65. Schwedhelm, E. Quantification of ADMA: analytical approaches. Vasc Med, 2005, 10 (Suppl 1), S89-95.
66. Tsikas, D.; Junker, W.; Frolich, J. C. Determination of dimethylated arginines in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl, 1998, 705, 174-176.
67. Sotgia, S.; Zinellu, A.; Pinna, G. A.; Deiana, L.; Carru, C. A new selective pre-column ninhydrin-based derivatization for a RP-HPLC determination of plasma asymmetric dimethyl-L-arginine (ADMA) by fluorescence detection. Amino Acids, 2008, 34, 677-682.
68. Martens-Lobenhoffer, J.; Bode-Boger, S. M. Chromatographic-mass spectrometric methods for the quantification of L-arginine and its methylated metabolites in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci, 2007, 851, 30-41.
69. Davids, M.; Swieringa, E.; Palm, F.; Smith, D. E.; Smulders, Y. M.; Scheffer, P. G.; Blom, H. J.; Teerlink, T. Simultaneous determination of asymmetric and symmetric dimethylarginine, L-monomethylarginine, L-arginine, and L-homoarginine in biological samples using stable isotope dilution liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2012, 900, 38-47.
70. El-Khoury, J. M.; Bunch, D. R.; Reineks, E.; Jackson, R.; Steinle, R.; Wang, S. A simple and fast liquid chromatography-tandem mass spectrometry method for measurement of underivatized L-arginine, symmetric dimethylarginine, and asymmetric dimethylarginine and establishment of the reference ranges. Anal Bioanal Chem, 2012, 402, 771-779.
71. Martens-Lobenhoffer, J.; Bode-Boger, S. M. Quantification of L-arginine, asymmetric dimethylarginine and symmetric dimethylarginine in human plasma: a step improvement in precision by stable isotope dilution mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci, 2012, 904, 140-143.
72. Tsikas, D.; Schubert, B.; Gutzki, F. M.; Sandmann, J.; Frolich, J. C. Quantitative determination of circulating and urinary asymmetric dimethylarginine (ADMA) in humans by gas chromatography-tandem mass spectrometry as methyl ester tri(N-pentafluoropropionyl) derivative. J Chromatogr B Analyt Technol Biomed Life Sci, 2003, 798, 87-99.
73. Tsikas, D.; Beckmann, B.; Gutzki, F. M.; Jordan, J. Simultaneous gas chromatography-tandem mass spectrometry quantification of symmetric and asymmetric dimethylarginine in human urine. Anal Biochem, 2011, 413, 60-62.
74. Yokoro, M.; Suzuki, M.; Yatani, M.; Yamashita, H.; Takahashi, Y.; Tsuji, H.; Kimoto, M. Development of an enzyme-linked immunosorbent assay system for the determination of asymmetric dimethylarginine using a specific monoclonal antibody. Biosci Biotechnol Biochem, 2012, 76, 400-403.
75. Schulze, F.; Wesemann, R.; Schwedhelm, E.; Sydow, K.; Albsmeier, J.; Cooke, J. P.; Boger, R. H. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin Chem Lab Med, 2004, 42, 1377-1383.
76. Martens-Lobenhoffer, J.; Westphal, S.; Awiszus, F.; Bode-Boger, S. M.; Luley, C. Determination of asymmetric dimethylarginine: liquid chromatography-mass spectrometry or ELISA? Clin Chem, 2005, 51, 2188-2189.
77. Schulze, F.; Schwedhelm, E.; Maas, R.; Boger, R. H. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J Chromatogr B Analyt Technol Biomed Life Sci, 2006, 831, 333.
78. Furchgott, R. F.; Zawadzki, J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 1980, 288, 373-376.
79. Bauer, V.; Sotnikova, R. Nitric oxide--the endothelium-derived relaxing factor and its role in endothelial functions. Gen Physiol Biophys, 2010, 29, 319-340.
80. Moncada, S.; Higgs, A. The L-arginine-nitric oxide pathway. N Engl J Med, 1993, 329, 2002-2012.
81. Klabunde, R. E. Cardiovascular Physiology Concepts. Lippincott Williams & Wilkins 2011.
82. Radomski, M. W.; Moncada, S. The biological and pharmacological role of nitric oxide in platelet function. Adv Exp Med Biol, 1993, 344, 251-264.
83. McNamara, D. B.; Bedi, B.; Aurora, H.; Tena, L.; Ignarro, L. J.; Kadowitz, P. J.; Akers, D. L. L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun, 1993, 193, 291-296.
84. Upchurch, G. R., Jr.; Ford, J. W.; Weiss, S. J.; Knipp, B. S.; Peterson, D. A.; Thompson, R. W.; Eagleton, M. J.; Broady, A. J.; Proctor, M. C.; Stanley, J. C. Nitric oxide inhibition increases matrix metalloproteinase-9 expression by rat aortic smooth muscle cells in vitro. J Vasc Surg, 2001, 34, 76-83.
85. Cai, H.; Harrison, D. G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res, 2000, 87, 840-844.
86. Bath, P. M.; Hassall, D. G.; Gladwin, A. M.; Palmer, R. M.; Martin, J. F. Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb, 1991, 11, 254-260.
87. De Caterina, R.; Libby, P.; Peng, H. B.; Thannickal, V. J.; Rajavashisth, T. B.; Gimbrone, M. A., Jr.; Shin, W. S.; Liao, J. K. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest, 1995, 96, 60-68.
88. Gryglewski, R. J.; Palmer, R. M.; Moncada, S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature, 1986, 320, 454-456.
89. Mugge, A.; Elwell, J. H.; Peterson, T. E.; Harrison, D. G. Release of intact endothelium-derived relaxing factor depends on endothelial superoxide dismutase activity. Am J Physiol, 1991, 260, C219-225.
90. Schnackenberg, C. G.; Welch, W. J.; Wilcox, C. S. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension, 1998, 32, 59-64.
91. Cosentino, F.; Hishikawa, K.; Katusic, Z. S.; Luscher, T. F. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation, 1997, 96, 25-28.
92. Vallance, P.; Chan, N. Endothelial function and nitric oxide: clinical relevance. Heart, 2001, 85, 342-350.
93. Faraci, F. M.; Brian, J. E., Jr.; Heistad, D. D. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase. Am J Physiol, 1995, 269, H1522-1527.
94. Cooke, J. P. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol, 2000, 20, 2032-2037.
95. Verhaar, M. C.; Westerweel, P. E.; van Zonneveld, A. J.; Rabelink, T. J. Free radical production by dysfunctional eNOS. Heart, 2004, 90, 494-495.
96. Wever, R. M.; van Dam, T.; van Rijn, H. J.; de Groot, F.; Rabelink, T. J. Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase. Biochem Biophys Res Commun, 1997, 237, 340-344.
97. Veresh, Z.; Racz, A.; Lotz, G.; Koller, A. ADMA impairs nitric oxide-mediated arteriolar function due to increased superoxide production by angiotensin II-NAD(P)H oxidase pathway. Hypertension, 2008, 52, 960-966.
98. Boger, R. H.; Bode-Boger, S. M.; Tsao, P. S.; Lin, P. S.; Chan, J. R.; Cooke, J. P. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol, 2000, 36, 2287-2295.
99. Bode-Boger, S. M.; Scalera, F.; Martens-Lobenhoffer, J. Asymmetric dimethylarginine (ADMA) accelerates cell senescence. Vasc Med, 2005, 10 (Suppl 1), S65-71.
100. Wells, S. M.; Holian, A. Asymmetric dimethylarginine induces oxidative and nitrosative stress in murine lung epithelial cells. Am J Respir Cell Mol Biol, 2007, 36, 520-528.
101. Antoniades, C.; Shirodaria, C.; Leeson, P.; Antonopoulos, A.; Warrick, N.; Van-Assche, T.; Cunnington, C.; Tousoulis, D.; Pillai, R.; Ratnatunga, C.; Stefanadis, C.; Channon, K. M. Association of plasma asymmetrical dimethylarginine (ADMA) with elevated vascular superoxide production and endothelial nitric oxide synthase uncoupling: implications for endothelial function in human atherosclerosis. Eur Heart J, 2009, 30, 1142-1150.
102. Mohan, S.; Fung, H. L. Mechanism of cellular oxidation stress induced by asymmetric dimethylarginine. Int J Mol Sci, 2012, 13, 7521-7531.
103. Bai, Y.; Sun, L.; Du, L.; Zhang, T.; Xin, W.; Lan, X.; Du, G. Association of circulating levels of asymmetric dimethylarginine (ADMA) with carotid intima-media thickness: Evidence from 6168 participants. Ageing Res Rev, 2012.
104. Juonala, M.; Viikari, J. S.; Alfthan, G.; Marniemi, J.; Kahonen, M.; Taittonen, L.; Laitinen, T.; Raitakari, O. T. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation, 2007, 116, 1367-1373.
105. Paiva, H.; Kahonen, M.; Lehtimaki, T.; Alfthan, G.; Viikari, J.; Laaksonen, R.; Hutri-Kahonen, N.; Laitinen, T.; Taittonen, L.; Raitakari, O. T.; Juonala, M. Levels of asymmetrical dimethylarginine are predictive of brachial artery flow-mediated dilation 6 years later. The Cardiovascular Risk in Young Finns Study. Atherosclerosis, 2010, 212, 512-515.
106. Antoniades, C.; Demosthenous, M.; Tousoulis, D.; Antonopoulos, A. S.; Vlachopoulos, C.; Toutouza, M.; Marinou, K.; Bakogiannis, C.; Mavragani, K.; Lazaros, G.; Koumallos, N.; Triantafyllou, C.; Lymperiadis, D.; Koutsilieris, M.; Stefanadis, C. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension, 2011, 58, 93-98.
107. Hsu, C. N.; Huang, L. T.; Lau, Y. T.; Lin, C. Y.; Tain, Y. L. The combined ratios of L-arginine and asymmetric and symmetric dimethylarginine as biomarkers in spontaneously hypertensive rats. Transl Res, 2012, 159, 90-98.
108. Tain, Y. L.; Huang, L. T.; Lin, I. C.; Lau, Y. T.; Lin, C. Y. Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats. J Pineal Res, 2010, 49, 390-398.
109. Curgunlu, A.; Uzun, H.; Bavunoglu, I.; Karter, Y.; Genc, H.; Vehid, S. Increased circulating concentrations of asymmetric dimethylarginine (ADMA) in white coat hypertension. J Hum Hypertens, 2005, 19, 629-633.
110. Franklin, S. S.; Thijs, L.; Hansen, T. W.; Li, Y.; Boggia, J.; Kikuya, M.; Bjorklund-Bodegard, K.; Ohkubo, T.; Jeppesen, J.; Torp-Pedersen, C.; Dolan, E.; Kuznetsova, T.; Stolarz-Skrzypek, K.; Tikhonoff, V.; Malyutina, S.; Casiglia, E.; Nikitin, Y.; Lind, L.; Sandoya, E.; Kawecka-Jaszcz, K.; Imai, Y.; Wang, J.; Ibsen, H.; O'Brien, E.; Staessen, J. A. Significance of white-coat hypertension in older persons with isolated systolic hypertension: a meta-analysis using the International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes population. Hypertension, 2012, 59, 564-571.
111. Verdecchia, P.; Staessen, J. A.; White, W. B.; Imai, Y.; O'Brien, E. T. Properly defining white coat hypertension. Eur Heart J, 2002, 23, 106-109.
112. Wang, H.; Liu, J. Plasma asymmetric dimethylarginine and L-arginine levels in Chinese patients with essential hypertension without coronary artery disease. J Cardiovasc Dis Res, 2011, 2, 177-180.
113. Tsioufis, C.; Dimitriadis, K.; Andrikou, E.; Thomopoulos, C.; Tsiachris, D.; Stefanadi, E.; Mihas, C.; Miliou, A.; Papademetriou, V.; Stefanadis, C. ADMA, C-reactive protein, and albuminuria in untreated essential hypertension: a cross-sectional study. Am J Kidney Dis, 2010, 55, 1050-1059.
114. Fujii, H.; Takiuchi, S.; Kawano, Y.; Fukagawa, M. Putative role of asymmetric dimethylarginine in microvascular disease of kidney and heart in hypertensive patients. Am J Hypertens, 2008, 21, 650-656.
115. Perticone, F.; Sciacqua, A.; Maio, R.; Perticone, M.; Maas, R.; Boger, R. H.; Tripepi, G.; Sesti, G.; Zoccali, C. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol, 2005, 46, 518-523.
116. Bai, Y.; Hui, R. Dimethylarginine dimethylaminohydrolase (DDAH)--a critical regulator of hypertensive left ventricular hypertrophy? Med Hypotheses, 2008, 70, 962-966.
117. Sladek, T.; Gerova, M.; Znojil, V.; Devat, L. Morphometric characteristics of cardiac hypertrophy induced by long-term inhibition of NO synthase. Physiol Res, 1996, 45, 335-338.
118. Fujiwara, N.; Osanai, T.; Kamada, T.; Katoh, T.; Takahashi, K.; Okumura, K. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation, 2000, 101, 856-861.
119. Wang, D.; Strandgaard, S.; Iversen, J.; Wilcox, C. S. Asymmetric dimethylarginine, oxidative stress, and vascular nitric oxide synthase in essential hypertension. Am J Physiol Regul Integr Comp Physiol, 2009, 296, R195-200.
120. Takiuchi, S.; Fujii, H.; Kamide, K.; Horio, T.; Nakatani, S.; Hiuge, A.; Rakugi, H.; Ogihara, T.; Kawano, Y. Plasma asymmetric dimethylarginine and coronary and peripheral endothelial dysfunction in hypertensive patients. Am J Hypertens, 2004, 17, 802-808.
121. Perticone, F.; Sciacqua, A.; Maio, R.; Perticone, M.; Galiano Leone, G.; Bruni, R.; Di Cello, S.; Pascale, A.; Talarico, G.; Greco, L.; Andreozzi, F.; Sesti, G. Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int J Cardiol, 2010, 142, 236-241.
122. Delles, C.; Schneider, M. P.; John, S.; Gekle, M.; Schmieder, R. E. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens, 2002, 15, 590-593.
123. Kawata, T.; Daimon, M.; Hasegawa, R.; Teramoto, K.; Toyoda, T.; Sekine, T.; Yamamoto, K.; Uchida, D.; Himi, T.; Yoshida, K.; Komuro, I. Effect of angiotensin-converting enzyme inhibitor on serum asymmetric dimethylarginine and coronary circulation in patients with type 2 diabetes mellitus. Int J Cardiol, 2009, 132, 286-288.
124. Tain, Y. L.; Hsu, C. N.; Lin, C. Y.; Huang, L. T.; Lau, Y. T. Aliskiren prevents hypertension and reduces asymmetric dimethylarginine in young spontaneously hypertensive rats. Eur J Pharmacol, 2011, 670, 561-565.
125. Li, D.; Xia, K.; Li, N. S.; Luo, D.; Wang, S.; Jiang, D. J.; Deng, H. W.; Li, Y. J. Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats. Can J Physiol Pharmacol, 2007, 85, 783-789.
126. Oguz, A.; Uzunlulu, M.; Yorulmaz, E.; Yalcin, Y.; Hekim, N.; Fici, F. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus. Anadolu Kardiyol Derg, 2007, 7, 383-387.
127. Garbin, U.; Pasini, A. F.; Stranieri, C.; Manfro, S.; Boccioletti, V.; Cominacini, L. Nebivolol reduces asymmetric dimethylarginine in endothelial cells by increasing dimethylarginine dimethylaminohydrolase 2 (DDAH2) expression and activity. Pharmacol Res, 2007, 56, 515-521.
128. Chobanyan-Jurgens, K.; Fuchs, A. J.; Tsikas, D.; Kanzelmeyer, N.; Das, A. M.; Illsinger, S.; Vaske, B.; Jordan, J.; Lucke, T. Increased asymmetric dimethylarginine (ADMA) dimethylaminohydrolase (DDAH) activity in childhood hypercholesterolemia type II. Amino Acids, 2012, 43, 805-811.
129. Jehlicka, P.; Stozicky, F.; Mayer, O., Jr.; Varvarovska, J.; Racek, J.; Trefil, L.; Siala, K. Asymmetric dimethylarginine and the effect of folate substitution in children with familial hypercholesterolemia and diabetes mellitus type 1. Physiol Res, 2009, 58, 179-184.
130. Stuhlinger, M. C.; Abbasi, F.; Chu, J. W.; Lamendola, C.; McLaughlin, T. L.; Cooke, J. P.; Reaven, G. M.; Tsao, P. S. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA, 2002, 287, 1420-1426.
131. Panichi, V.; Mantuano, E.; Paoletti, S.; Santi, S.; Manca Rizza, G.; Cutrupi, S.; Pizzini, P.; Spoto, B.; Tripepi, G.; Zoccali, C. Effect of simvastatin on plasma asymmetric dimethylarginine concentration in patients with chronic kidney disease. J Nephrol, 2008, 21, 38-44.
132. Vladimirova-Kitova, L.; Deneva, T.; Marinov, B. Predictors of the intima-media thickness of carotid artery in asymptomatic newly detected severe hypercholesterolemic patients. Clin Physiol Funct Imaging, 2010, 30, 250-259.
133. Vladimirova-Kitova, L.; Deneva, T.; Angelova, E.; Nikolov, F.; Marinov, B.; Mateva, N. Relationship of asymmetric dimethylarginine with flow-mediated dilatation in subjects with newly detected severe hypercholesterolemia. Clin Physiol Funct Imaging, 2008, 28, 417-425.
134. Eid, H. M.; Arnesen, H.; Hjerkinn, E. M.; Lyberg, T.; Seljeflot, I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism, 2004, 53, 1574-1579.
135. Siervo, M.; Bluck, L. J. In vivo nitric oxide synthesis, insulin sensitivity, and asymmetric dimethylarginine in obese subjects without and with metabolic syndrome. Metabolism, 2012, 61, 680-688.
136. Garcia, R. G.; Perez, M.; Maas, R.; Schwedhelm, E.; Boger, R. H.; Lopez-Jaramillo, P. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int J Cardiol, 2007, 122, 176-178.
137. Young, J. M.; Strey, C. H.; George, P. M.; Florkowski, C. M.; Sies, C. W.; Frampton, C. M.; Scott, R. S. Effect of atorvastatin on plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure. Eur J Heart Fail, 2008, 10, 463-466.
138. Eid, H. M.; Eritsland, J.; Larsen, J.; Arnesen, H.; Seljeflot, I. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis, 2003, 166, 279-284.
139. Lu, T. M.; Ding, Y. A.; Leu, H. B.; Yin, W. H.; Sheu, W. H.; Chu, K. M. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol, 2004, 94, 157-161.
140. Pei, Y.; Ma, P.; Wang, X.; Zhang, W.; Zhang, X.; Zheng, P.; Yan, L.; Xu, Q.; Dai, G. Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism. Eur J Pharmacol, 2011, 666, 165-172.
141. Vladimirova-Kitova, L. G.; Deneva-Koycheva, T. Asymmetric dimethylarginine--a determinant of the effect of the high dose Simvastatin. Clin Biochem, 2010, 43, 843-850.
142. Boger, G. I.; Rudolph, T. K.; Maas, R.; Schwedhelm, E.; Dumbadze, E.; Bierend, A.; Benndorf, R. A.; Boger, R. H. Asymmetric dimethylarginine determines the improvement of endothelium-dependent vasodilation by simvastatin: Effect of combination with oral L-arginine. J Am Coll Cardiol, 2007, 49, 2274-2282.
143. Janatuinen, T.; Laakso, J.; Laaksonen, R.; Vesalainen, R.; Nuutila, P.; Lehtimaki, T.; Raitakari, O. T.; Knuuti, J. Plasma asymmetric dimethylarginine modifies the effect of pravastatin on myocardial blood flow in young adults. Vasc Med, 2003, 8, 185-189.
144. Munzel, T.; Sinning, C.; Post, F.; Warnholtz, A.; Schulz, E. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med, 2008, 40, 180-196.
145. Altinova, A. E.; Arslan, M.; Sepici-Dincel, A.; Akturk, M.; Altan, N.; Toruner, F. B. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab, 2007, 92, 1881-1885.
146. Mittermayer, F.; Pleiner, J.; Krzyzanowska, K.; Wiesinger, G. F.; Francesconi, M.; Wolzt, M. Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with type 1 diabetes mellitus. Wien Klin Wochenschr, 2005, 117, 816-820.
147. Ito, A.; Egashira, K.; Narishige, T.; Muramatsu, K.; Takeshita, A. Angiotensin-converting enzyme activity is involved in the mechanism of increased endogenous nitric oxide synthase inhibitor in patients with type 2 diabetes mellitus. Circ J, 2002, 66, 811-815.
148. Devangelio, E.; Santilli, F.; Formoso, G.; Ferroni, P.; Bucciarelli, L.; Michetti, N.; Clissa, C.; Ciabattoni, G.; Consoli, A.; Davi, G. Soluble RAGE in type 2 diabetes: association with oxidative stress. Free Radic Biol Med, 2007, 43, 511-518.
149. Sibal, L.; Agarwal, S. C.; Schwedhelm, E.; Luneburg, N.; Boger, R. H.; Home, P. D. A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria. Cardiovasc Diabetol, 2009, 8, 27.
150. Paiva, H.; Lehtimaki, T.; Laakso, J.; Ruokonen, I.; Rantalaiho, V.; Wirta, O.; Pasternack, A.; Laaksonen, R. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism, 2003, 52, 303-307.
151. Ellger, B.; Richir, M. C.; van Leeuwen, P. A.; Debaveye, Y.; Langouche, L.; Vanhorebeek, I.; Teerlink, T.; Van den Berghe, G. Glycemic control modulates arginine and asymmetrical-dimethylarginine levels during critical illness by preserving dimethylarginine-dimethylaminohydrolase activity. Endocrinology, 2008, 149, 3148-3157.
152. Asagami, T.; Abbasi, F.; Stuelinger, M.; Lamendola, C.; McLaughlin, T.; Cooke, J. P.; Reaven, G. M.; Tsao, P. S. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism, 2002, 51, 843-846.
153. Achan, V.; Tran, C. T.; Arrigoni, F.; Whitley, G. S.; Leiper, J. M.; Vallance, P. all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res, 2002, 90, 764-769.
154. Bestermann, W. H., Jr. The ADMA-Metformin Hypothesis: Linking the Cardiovascular Consequences of the Metabolic Syndrome and Type 2 Diabetes. Cardiorenal Med, 2011, 1, 211-219.
155. Das, U. N.; Repossi, G.; Dain, A.; Eynard, A. R. L-arginine, NO and asymmetrical dimethylarginine in hypertension and type 2 diabetes. Front Biosci, 2011, 16, 13-20.
156. Lajer, M.; Tarnow, L.; Jorsal, A.; Teerlink, T.; Parving, H. H.; Rossing, P. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care, 2008, 31, 747-752.
157. Krzyzanowska, K.; Mittermayer, F.; Wolzt, M.; Schernthaner, G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care, 2007, 30, 1834-1839.
158. Kanazawa, I.; Yano, S.; Notsu, Y.; Yamaguchi, T.; Nabika, T.; Sugimoto, T. Asymmetric dimethylarginine as a risk factor for cardiovascular disease in Japanese patients with type 2 diabetes mellitus. Clin Endocrinol (Oxf), 2011, 74, 467-472.
159. Lu, T. M.; Chung, M. Y.; Lin, M. W.; Hsu, C. P.; Lin, S. J. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol, 2011, 153, 135-140.
160. Imamura, M.; Waseda, Y.; Marinova, G. V.; Ishibashi, T.; Obayashi, S.; Sasaki, A.; Nagai, A.; Azuma, H. Alterations of NOS, arginase, and DDAH protein expression in rabbit cavernous tissue after administration of cigarette smoke extract. Am J Physiol Regul Integr Comp Physiol, 2007, 293, R2081-2089.
161. Zhang, W. Z.; Venardos, K.; Chin-Dusting, J.; Kaye, D. M. Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress. Hypertension, 2006, 48, 278-285.
162. Sobczak, A.; Szoltysek-Boldys, I.; Grela, W.; Zielinska-Danch, W. [Does tobacco smoke influence the concentration of asymmetric dimethylarginine (ADMA) in healthy males plasma?]. Przegl Lek, 2007, 64, 698-702.
163. Lucke, T.; Kanzelmeyer, N.; Kemper, M. J.; Tsikas, D.; Das, A. M. Developmental changes in the L-arginine/nitric oxide pathway from infancy to adulthood: plasma asymmetric dimethylarginine levels decrease with age. Clin Chem Lab Med, 2007, 45, 1525-1530.
164. Kielstein, J. T.; Bode-Boger, S. M.; Frolich, J. C.; Ritz, E.; Haller, H.; Fliser, D. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation, 2003, 107, 1891-1895.
165. Fabian, E.; Bogner, M.; Elmadfa, I. Age-related modification of antioxidant enzyme activities in relation to cardiovascular risk factors. Eur J Clin Invest, 2012, 42, 42-48.
166. Zoccali, C.; Bode-Boger, S.; Mallamaci, F.; Benedetto, F.; Tripepi, G.; Malatino, L.; Cataliotti, A.; Bellanuova, I.; Fermo, I.; Frolich, J.; Boger, R. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet, 2001, 358, 2113-2117.
167. Valkonen, V. P.; Paiva, H.; Salonen, J. T.; Lakka, T. A.; Lehtimaki, T.; Laakso, J.; Laaksonen, R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet, 2001, 358, 2127-2128.
168. Maas, R.; Schulze, F.; Baumert, J.; Lowel, H.; Hamraz, K.; Schwedhelm, E.; Koenig, W.; Boger, R. H. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem, 2007, 53, 693-701.
169. Zeller, M.; Korandji, C.; Guilland, J. C.; Sicard, P.; Vergely, C.; Lorgis, L.; Beer, J. C.; Duvillard, L.; Lagrost, A. C.; Moreau, D.; Gambert, P.; Cottin, Y.; Rochette, L. Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol, 2008, 28, 954-960.
170. Tonstad, S.; Thorsrud, H.; Torjesen, P. A.; Seljeflot, I. Do novel risk factors differ between men and women aged 18 to 39 years with a high risk of coronary heart disease? Metabolism, 2007, 56, 260-266.
171. Cavusoglu, E.; Ruwende, C.; Chopra, V.; Poludasu, S.; Yanamadala, S.; Frishman, W. H.; Eng, C.; Pinsky, D. J.; Marmur, J. D. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis, 2010, 210, 226-231.
172. Cao, Y.; Yang, K.; Zhang, Z.; Ouyang, M.; Xiao, L. Correlation between plasma asymmetric dimethylarginine and different types of coronary heart disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 2010, 35, 301-306.
173. Djordjevic, B. V.; Pavlovic, R.; Cosic, V.; Deljanin-Ilic, M.; Ristic, T.; Krstic, N.; Jevtovic-Stoimenov, T. High clinical accuracy of asymmetric dimethylarginine and symmetric dimethylarginine in patients with ischemic heart disease. Amino Acids, 2012.
174. Krempl, T. K.; Maas, R.; Sydow, K.; Meinertz, T.; Boger, R. H.; Kahler, J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J, 2005, 26, 1846-1851.
175. Sen, N.; Ozlu, M. F.; Akgul, E. O.; Kanat, S.; Cayci, T.; Turak, O.; Yaman, H.; Sokmen, E.; Ozcan, F.; Maden, O.; Demir, A. D.; Covic, A.; Kanbay, M. Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion. Atherosclerosis, 2011, 219, 304-310.
176. Lu, T. M.; Ding, Y. A.; Lin, S. J.; Lee, W. S.; Tai, H. C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J, 2003, 24, 1912-1919.
177. Derkacz, A.; Protasiewicz, M.; Poreba, R.; Doroszko, A.; Poreba, M.; Antonowicz-Juchniewicz, J.; Andrzejak, R.; Szuba, A. Plasma asymmetric dimethylarginine predicts restenosis after coronary angioplasty. Arch Med Sci, 2011, 7, 444-448.
178. Schulze, F.; Lenzen, H.; Hanefeld, C.; Bartling, A.; Osterziel, K. J.; Goudeva, L.; Schmidt-Lucke, C.; Kusus, M.; Maas, R.; Schwedhelm, E.; Strodter, D.; Simon, B. C.; Mugge, A.; Daniel, W. G.; Tillmanns, H.; Maisch, B.; Streichert, T.; Boger, R. H. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J, 2006, 152, 493 e491-498.
179. Schnabel, R.; Blankenberg, S.; Lubos, E.; Lackner, K. J.; Rupprecht, H. J.; Espinola-Klein, C.; Jachmann, N.; Post, F.; Peetz, D.; Bickel, C.; Cambien, F.; Tiret, L.; Munzel, T. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res, 2005, 97, e53-59.
180. Meinitzer, A.; Seelhorst, U.; Wellnitz, B.; Halwachs-Baumann, G.; Boehm, B. O.; Winkelmann, B. R.; Marz, W. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem, 2007, 53, 273-283.
181. Bishu, K.; Deswal, A.; Chen, H. H.; Lewinter, M. M.; Lewis, G. D.; Semigran, M. J.; Borlaug, B. A.; McNulty, S.; Hernandez, A. F.; Braunwald, E.; Redfield, M. M. Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. Am Heart J, 2012, 164, 763-770 e763.
182. Tousoulis, D.; Oikonomou, E.; Siasos, G.; Chrysohoou, C.; Charakida, M.; Trikas, A.; Siasou, Z.; Limperi, M.; Papadimitriou, E. D.; Papavassiliou, A. G.; Stefanadis, C. Predictive value of biomarkers in patients with heart failure. Curr Med Chem, 2012, 19, 2534-2547.
183. Shapiro, B. P.; Chen, H. H.; Burnett, J. C., Jr.; Redfield, M. M. Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure. Mayo Clin Proc, 2003, 78, 481-486.
184. Sharma, R.; Coats, A. J.; Anker, S. D. The role of inflammatory mediators in chronic heart failure: cytokines, nitric oxide, and endothelin-1. Int J Cardiol, 2000, 72, 175-186.
185. Shi, B.; Ni, Z.; Zhou, W.; Yu, Z.; Gu, L.; Mou, S.; Fang, W.; Wang, Q.; Cao, L.; Yan, Y.; Qian, J. Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease. Eur J Intern Med, 2010, 21, 444-448.
186. von Haehling, S.; Bode-Boger, S. M.; Martens-Lobenhoffer, J.; Rauchhaus, M.; Schefold, J. C.; Genth-Zotz, S.; Karhausen, T.; Cicoira, M.; Anker, S. D.; Doehner, W. Elevated levels of asymmetric dimethylarginine in chronic heart failure: a pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol. Clin Pharmacol Ther, 2010, 88, 506-512.
187. Seljeflot, I.; Nilsson, B. B.; Westheim, A. S.; Bratseth, V.; Arnesen, H. The L-arginine-asymmetric dimethylarginine ratio is strongly related to the severity of chronic heart failure. No effects of exercise training. J Card Fail, 2011, 17, 135-142.
188. Bart, B. A.; Shaw, L. K.; McCants, C. B., Jr.; Fortin, D. F.; Lee, K. L.; Califf, R. M.; O'Connor, C. M. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol, 1997, 30, 1002-1008.
189. Hsu, C. P.; Lin, S. J.; Chung, M. Y.; Lu, T. M. Asymmetric dimethylarginine predicts clinical outcomes in ischemic chronic heart failure. Atherosclerosis, 2012.
190. Duckelmann, C.; Mittermayer, F.; Haider, D. G.; Altenberger, J.; Eichinger, J.; Wolzt, M. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol, 2007, 27, 2037-2042.
191. Nicholls, S. J.; Wang, Z.; Koeth, R.; Levison, B.; DelFraino, B.; Dzavik, V.; Griffith, O. W.; Hathaway, D.; Panza, J. A.; Nissen, S. E.; Hochman, J. S.; Hazen, S. L. Metabolic profiling of arginine and nitric oxide pathways predicts hemodynamic abnormalities and mortality in patients with cardiogenic shock after acute myocardial infarction. Circulation, 2007, 116, 2315-2324.
192. Saitoh, M.; Osanai, T.; Kamada, T.; Matsunaga, T.; Ishizaka, H.; Hanada, H.; Okumura, K. High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. Heart Vessels, 2003, 18, 177-182.
193. Shao, Z.; Wang, Z.; Shrestha, K.; Thakur, A.; Borowski, A. G.; Sweet, W.; Thomas, J. D.; Moravec, C. S.; Hazen, S. L.; Tang, W. H. Pulmonary hypertension associated with advanced systolic heart failure: dysregulated arginine metabolism and importance of compensatory dimethylarginine dimethylaminohydrolase-1. J Am Coll Cardiol, 2012, 59, 1150-1158.
194. Zairis, M. N.; Patsourakos, N. G.; Tsiaousis, G. Z.; Theodossis Georgilas, A.; Melidonis, A.; Makrygiannis, S. S.; Velissaris, D.; Batika, P. C.; Argyrakis, K. S.; Tzerefos, S. P.; Prekates, A. A.; Foussas, S. G. Plasma asymmetric dimethylarginine and mortality in patients with acute decompensation of chronic heart failure. Heart, 2012, 98, 860-864.
195. Ngo, D. T.; Heresztyn, T.; Mishra, K.; Marwick, T. H.; Horowitz, J. D. Aortic stenosis is associated with elevated plasma levels of asymmetric dimethylarginine (ADMA). Nitric Oxide, 2007, 16, 197-201.
196. Liu, H.; Qu, X.; Liang, Z.; Chen, W.; Xia, W.; Song, Y. Variance of DDAH/PRMT/ADMA pathway in atrial fibrillation dogs. Biochem Biophys Res Commun, 2008, 377, 884-888.
197. Deftereos, S.; Giannopoulos, G.; Kossyvakis, C.; Efremidis, M.; Panagopoulou, V.; Kaoukis, A.; Raisakis, K.; Bouras, G.; Angelidis, C.; Theodorakis, A.; Driva, M.; Doudoumis, K.; Pyrgakis, V.; Stefanadis, C. Colchicine for prevention of early atrial fibrillation recurrence after pulmonary vein isolation: a randomized controlled study. J Am Coll Cardiol, 2012, 60, 1790-1796.
198. Goette, A.; Hammwohner, M.; Bukowska, A.; Scalera, F.; Martens-Lobenhoffer, J.; Dobrev, D.; Ravens, U.; Weinert, S.; Medunjanin, S.; Lendeckel, U.; Bode-Boger, S. M. The impact of rapid atrial pacing on ADMA and endothelial NOS. Int J Cardiol, 2012, 154, 141-146.
199. Xia, W.; Qu, X.; Yu, Y.; Zhang, X.; Feng, W.; Song, Y. Asymmetric dimethylarginine concentration and early recurrence of atrial fibrillation after electrical cardioversion. Pacing Clin Electrophysiol, 2008, 31, 1036-1040.
200. Xia, W.; Yin, Z.; Li, J.; Song, Y.; Qu, X. Effects of rosuvastatin on asymmetric dimethylarginine levels and early atrial fibrillation recurrence after electrical cardioversion. Pacing Clin Electrophysiol, 2009, 32, 1562-1566.
201. Tveit, A.; Arnesen, H.; Smith, P.; Bratseth, V.; Seljeflot, I. L-arginine, asymmetric dimethylarginine and rhythm outcome after electrical cardioversion for atrial fibrillation. Cardiology, 2010, 117, 176-180.
202. Lehmann, H. I.; Goette, A.; Martens-Lobenhoffer, J.; Hammwohner, M.; Rohl, F. W.; Bukowska, A.; Ghanem, A.; Klein, H. U.; Bode-Boger, S. M. Asymmetric dimethylarginine predicts appropriate implantable cardioverter-defibrillator intervention in patients with left ventricular dysfunction. Europace, 2011, 13, 1428-1435.
203. Jin, J. S.; D'Alecy, L. G. Central and peripheral effects of asymmetric dimethylarginine, an endogenous nitric oxide synthetase inhibitor. J Cardiovasc Pharmacol, 1996, 28, 439-446.
204. Segarra, G.; Medina, P.; Ballester, R. M.; Lluch, P.; Aldasoro, M.; Vila, J. M.; Lluch, S.; Pelligrino, D. A. Effects of some guanidino compounds on human cerebral arteries. Stroke, 1999, 30, 2206-2210; discussion 2210-2211.
205. Yoo, J. H.; Lee, S. C. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis, 2001, 158, 425-430.
206. Wanby, P.; Teerlink, T.; Brudin, L.; Brattstrom, L.; Nilsson, I.; Palmqvist, P.; Carlsson, M. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis, 2006, 185, 271-277.
207. Khan, U.; Hassan, A.; Vallance, P.; Markus, H. S. Asymmetric dimethylarginine in cerebral small vessel disease. Stroke, 2007, 38, 411-413.
208. Chen, S.; Martens-Lobenhoffer, J.; Weissenborn, K.; Kielstein, J. T.; Lichtinghagen, R.; Deb, M.; Li, N.; Tryc, A. B.; Goldbecker, A.; Dong, Q.; Bode-Boger, S. M.; Worthmann, H. Association of dimethylarginines and mediators of inflammation after acute ischemic stroke. J Neuroinflammation, 2012, 9, 251.
209. Rueda-Clausen, C. F.; Cordoba-Porras, A.; Bedoya, G.; Silva, F. A.; Zarruk, J. G.; Lopez-Jaramillo, P.; Villa, L. A. Increased plasma levels of total homocysteine but not asymmetric dimethylarginine in Hispanic subjects with ischemic stroke FREC-VI sub-study. Eur J Neurol, 2012, 19, 417-425.
210. Mittermayer, F.; Krzyzanowska, K.; Exner, M.; Mlekusch, W.; Amighi, J.; Sabeti, S.; Minar, E.; Muller, M.; Wolzt, M.; Schillinger, M. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol, 2006, 26, 2536-2540.
211. Boger, R. H.; Endres, H. G.; Schwedhelm, E.; Darius, H.; Atzler, D.; Luneburg, N.; von Stritzky, B.; Maas, R.; Thiem, U.; Benndorf, R. A.; Diehm, C. Asymmetric dimethylarginine as an independent risk marker for mortality in ambulatory patients with peripheral arterial disease. J Intern Med, 2011, 269, 349-361.
212. Gorenflo, M.; Zheng, C.; Werle, E.; Fiehn, W.; Ulmer, H. E. Plasma levels of asymmetrical dimethyl-L-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol, 2001, 37, 489-492.
213. Loukanov, T.; Arnold, R.; Gross, J.; Sebening, C.; Klimpel, H.; Eichhorn, J.; Hoss, K.; Ulmer, H. E.; Kark, M.; Gorenflo, M. Endothelin-1 and asymmetric dimethylarginine in children with left-to-right shunt after intracardiac repair. Clin Res Cardiol, 2008, 97, 383-388.
214. Boger, R. H.; Ron, E. S. L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev, 2005, 10, 14-23.
215. Boger, R. H. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the L-arginine paradox and acts as a novel cardiovascular risk factor. J Nutr, 2004, 134, 2842S-2847S; discussion 2853S.
216. Chin-Dusting, J. P.; Alexander, C. T.; Arnold, P. J.; Hodgson, W. C.; Lux, A. S.; Jennings, G. L. Effects of in vivo and in vitro L-arginine supplementation on healthy human vessels. J Cardiovasc Pharmacol, 1996, 28, 158-166.
217. Schulman, S. P.; Becker, L. C.; Kass, D. A.; Champion, H. C.; Terrin, M. L.; Forman, S.; Ernst, K. V.; Kelemen, M. D.; Townsend, S. N.; Capriotti, A.; Hare, J. M.; Gerstenblith, G. L-arginine therapy in acute myocardial infarction: the Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. JAMA, 2006, 295, 58-64.
218. Beltowski, J.; Kedra, A. Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. Pharmacol Rep, 2006, 58, 159-178.